SCHEMBL7920140

SCHEMBL7920140

N#CCc1ccc(N2CCCCC2)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
POLB P06746 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A3 P47895 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.42
MAPK1 P28482 4/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
CSF1R P07333 5/20 0.41
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.39
USP2 O75604 1/20 0.39
RAB9A P51151 1/20 0.39
KCNQ2 O43526 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7906690 0.89 ALDH1A1 (0.46) ALDH1A1POLBL3MBTL1KDM4EALDH1A3
SCHEMBL195993 0.83 ALDH1A1 (0.51) ALDH1A1POLBL3MBTL1KDM4EGAA
SCHEMBL7906697 0.83 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2GAAHPGDHTT
SCHEMBL10237127 0.79 ALDH1A1 (0.41) ALDH1A1L3MBTL1KDM4ESMN1; SMN2MAPK1
SCHEMBL7913896 0.78 ALDH1A1 (0.56) ALDH1A1POLBKDM4EALDH1A3SMN1; SMN2
SCHEMBL5022655 0.78 ALDH1A1 (0.61) ALDH1A1POLBKDM4EALDH1A3SMN1; SMN2
SCHEMBL28144055 0.76 ALDH1A1 (0.50) ALDH1A1POLBL3MBTL1KDM4ESMN1; SMN2
SCHEMBL12497577 0.74 CHKA (0.47) ALDH1A1POLBL3MBTL1KDM4ESMN1; SMN2
SCHEMBL10237122 0.74 ALDH1A1 (0.41) ALDH1A1POLBL3MBTL1KDM4EALDH1A3
SCHEMBL29609180 0.73 IDO1 (0.52) POLBKDM4ESMN1; SMN2HPGDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754100-B2 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-17 US disclosed
US-8754100-B2 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-06-17 US disclosed
EP-2401276-B1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MAN CO LTD (JP) 2013-06-05 EP disclosed
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors EISAI R&D MANAGEMENT CO., LTD., (JP) 2012-03-01 US disclosed
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors EISAI R&D MANAGEMENT CO., LTD., (JP) 2012-03-01 US disclosed
WO-2010098487-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053171-A1 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors BACE1, APP, PSEN1 ALDH1A1 3158/4885POLB 2700/4885L3MBTL1 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.